A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.

Kamp GA, Mul D, Waelkens JJ, Jansen M, Delemarre-van de Waal HA, Verhoeven-Wind L, Frölich M, Oostdijk W, Wit JM

The Journal of clinical endocrinology and metabolism1 Jul 2001Cited by 37 (Europe PMC)

PMID11443153DOI10.1210/jcem.86.7.7650PepBankPUB-11443153

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In short children, height SD score for chronological age did not change in either the GH plus triptorelin group or controls.
In plain wordsHeight scores did not change in short children receiving GH plus triptorelin or in untreated controls.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeHeight SD score for chronological age
Study
n = 36
Comparator
Baseline in treated children and untreated controls
Outcome group
Linear growth · Endocrine and hormones
Source sentences
Summary
During 3 yr of study height SD score for chronological age did not change in both treated children and controls,
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR).
Summary · context
Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less in early puberty (girls, B2-3; boys, G2-3), were randomly assigned to treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa (triptorelin, 3.75 mg/28 days) or no treatment (n = 18).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1144315301
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In short children, GH plus triptorelin reduced bone maturation rate versus untreated controls.
In plain wordsIn short children, GH plus triptorelin slowed bone maturation compared with untreated controls.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone maturation rate
Study
n = 36
Comparator
Untreated controls
Outcome group
Linear growth · Endocrine and hormones
Measurements
Bone maturation rate
0.55 yr/yr
treated children
Bone maturation rate
1.15 yr/yr
controls
Source sentences
Summary
whereas a decreased rate of bone maturation after treatment was observed [mean (SD) 0.55 (0.21) 'yr'/yr vs. 1.15 (0.37) 'yr'/yr in controls, P < 0.001, girls and boys together].
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR).
Summary · context
Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less in early puberty (girls, B2-3; boys, G2-3), were randomly assigned to treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa (triptorelin, 3.75 mg/28 days) or no treatment (n = 18).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1144315302
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In short children, GH plus triptorelin did not influence body mass index.
In plain wordsIn short children, GH plus triptorelin did not change body mass index.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBody mass index
Study
n = 36
Comparator
Untreated controls
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Furthermore, the ratio between sitting height/height SD score decreased significantly in treated children, whereas body mass index was not influenced by treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR).
Summary · context
Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less in early puberty (girls, B2-3; boys, G2-3), were randomly assigned to treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa (triptorelin, 3.75 mg/28 days) or no treatment (n = 18).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1144315307
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In short children, the reported GH-dependent hormone and bone marker panel did not differ between GH plus triptorelin and controls.
In plain wordsIn short children, the hormone and bone marker panel did not differ between GH plus triptorelin and untreated controls.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeGH-dependent hormone and bone marker panel
Study
n = 36
Comparator
Untreated controls
Outcome group
Linear growth · Endocrine and hormones
Source sentences
Summary
GH-dependent hormones including serum insulin-like growth factor I and II, carboxy terminal propeptide of type I collagen, amino terminal propeptide of type III collagen, alkaline phosphatase, and osteocalcin were not different between treated children and controls during the study period.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR).
Summary · context
Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less in early puberty (girls, B2-3; boys, G2-3), were randomly assigned to treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa (triptorelin, 3.75 mg/28 days) or no treatment (n = 18).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1144315309
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In short children, GH plus triptorelin increased height SD score for bone age after treatment.
In plain wordsIn short children, GH plus triptorelin increased height scores for bone age compared with pretreatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseHeight SD score for bone age
Study
n = 18
Comparator
Pretreatment
Outcome group
Linear growth · Endocrine and hormones
Source sentences
Summary
Height SD score for bone age and predicted adult height increased significantly after 3 yr of treatment; compared with controls the predicted adult height gain was 8.0 cm in girls and 10.4 cm in boys.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR).
Summary · context
Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less in early puberty (girls, B2-3; boys, G2-3), were randomly assigned to treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa (triptorelin, 3.75 mg/28 days) or no treatment (n = 18).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1144315303
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In short children, the sitting height to height SD score ratio decreased during GH plus triptorelin treatment.
In plain wordsIn short children, the sitting height to height score ratio decreased during GH plus triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSitting height to height SD score ratio
Study
n = 18
Comparator
Pretreatment
Outcome group
Linear growth · Endocrine and hormones
Source sentences
Summary
Furthermore, the ratio between sitting height/height SD score decreased significantly in treated children, whereas body mass index was not influenced by treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR).
Summary · context
Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less in early puberty (girls, B2-3; boys, G2-3), were randomly assigned to treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa (triptorelin, 3.75 mg/28 days) or no treatment (n = 18).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1144315306
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In short children, GH plus triptorelin arrested puberty with prepubertal testosterone and estradiol levels.
In plain wordsIn short children, GH plus triptorelin stopped pubertal development with hormone levels in the prepubertal range.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePubertal arrest
Study
n = 18
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Puberty was effectively arrested in the treated children, as was confirmed by physical examination and prepubertal testosterone and estradiol levels.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR).
Summary · context
Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less in early puberty (girls, B2-3; boys, G2-3), were randomly assigned to treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa (triptorelin, 3.75 mg/28 days) or no treatment (n = 18).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1144315308
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In short girls, GH plus triptorelin increased predicted adult height by 8.0 cm compared with controls.
In plain wordsIn short girls, GH plus triptorelin increased predicted adult height by 8.0 cm compared with controls.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePredicted adult height gain in girls
Study
n: not reported in source
Comparator
Untreated controls
Outcome group
Linear growth · Endocrine and hormones
Measurements
Predicted adult height gain
8 cm
girls versus controls
Source sentences
Summary
Height SD score for bone age and predicted adult height increased significantly after 3 yr of treatment; compared with controls the predicted adult height gain was 8.0 cm in girls and 10.4 cm in boys.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR).
Summary · context
Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less in early puberty (girls, B2-3; boys, G2-3), were randomly assigned to treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa (triptorelin, 3.75 mg/28 days) or no treatment (n = 18).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1144315304
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In short boys, GH plus triptorelin increased predicted adult height by 10.4 cm compared with controls.
In plain wordsIn short boys, GH plus triptorelin increased predicted adult height by 10.4 cm compared with controls.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePredicted adult height gain in boys
Study
n: not reported in source
Comparator
Untreated controls
Outcome group
Linear growth · Endocrine and hormones
Measurements
Predicted adult height gain
10.4 cm
boys versus controls
Source sentences
Summary
Height SD score for bone age and predicted adult height increased significantly after 3 yr of treatment; compared with controls the predicted adult height gain was 8.0 cm in girls and 10.4 cm in boys.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR).
Summary · context
Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less in early puberty (girls, B2-3; boys, G2-3), were randomly assigned to treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa (triptorelin, 3.75 mg/28 days) or no treatment (n = 18).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1144315305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.